Barcelona, 3 March 2011. A clinical research trial led by Dr. Javier Cortés, the head of the BREAST CANCER Programme of the Vall d’Hebron Hospital and the VHIO, has demonstrated that eribulin (a chemotherapy drug based on Halichondria okadai, a sea sponge of animal origin) improves the prognosis of patients suffering from metastatic breast cancer. The trial, A Phase III open-label randomised study (EMBRACE) of eribulin monotherapy versus treatment of physician’s choice in patients with metastatic breast cancer, is being published today in The Lancet, and its objective was to demonstrate the efficacy of this treatment.
Related Posts
Marking melanoma cancer awareness month: Vall d´Hebron updates on its multidisciplinary and purely translational approach to more effectively treating this tumor type
The incidence of melanoma skin cancers has been substantially increasing over the past decades with an estimated 132,000 cases occurring…
23 May 2017
VHIO´s Joan Seoane elected as Fellow of the prestigious European Academy of Cancer Sciences
Launched back in 2009, the European Academy of Cancer Sciences, presided by Alexander M.M. Eggermont, also Director General of Gustave…
16 Oct 2017
Study shows marital status could impact on breast cancer prognosis
• An international study, with the participation of over 500,000 women, reveals that women who are married when diagnosed with breast cancer have a better chance of survival, regardless of tumor characteristics
• The study, in which the Vall d´Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO) have participated, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
28 May 2014
Antitumor agent improves survival of patients with treatment-resistant metastatic colorectal cancer
An international phase III study published in the New England Journal of Medicine (NEJM), in which the Vall d’Hebron University…
18 May 2015
VHIO collaborates in study identifying a novel therapeutic target for triple-negative breast cancer
• The PIM1 proto-oncogene evidenced as new therapeutic target through which to sensitize triple-negative breast tumours to chemotherapy• PIM1…
05 Nov 2016
Medical research safeguarded in Europe
ESMO welcomes the adoption of the Clinical Trials Regulation by the European Union Source: The European Society for Medical Oncology…
16 Jun 2014
VHIO Meet the Editors with Annals of Oncology´s Jean-Charles Soria, Monday 08 September 2014
Taking place on Monday 08 September 2014, beginning with a Welcome coffee at 14:15 – 14:30, followed by the main…
27 Jun 2014
Aggressiveness of breast cancer associated with longer lead times to metastasis
• Latest findings published in Cancer Research reveal that Luminal A breast cancer can switch subtype during time to metastasis…
24 Apr 2017
Presence of genetic mutation across several tumor types may help develop more precise anti-cancer therapies
• The phase II study, published in The New England Journal of Medicine, shows that the most common mutation of…
20 Aug 2015
FDA Allows WIN Consortium to Proceed with Targeted Tri-Therapy Clinical Trial in First Line Treatment of Metastatic Non Small Cell Lung Cancer
Source: WIN Consortium VILLEJUIF, France–(BUSINESS WIRE)– WIN Consortium (WIN) received the US Food and Drug Administration (FDA)’s approval to start…
09 Aug 2017
The Translational Biomedicine and Oncology Research Consortium has been created
It is the first National Agreement that includes the Academic environment, basic research, clinical research and the pharmaceutical industry
07 Sep 2010
Cancer Core Europe´s information hub: website now launched to update on the very latest from this inspired multi-center partnership
Launched in the Autumn of 2014, Cancer Core Europe is a working consortium that represents a critical mass of activity…
20 May 2016
Launched: VHIO´s Schools and Science Education Programme
VHIO opens its doors to bright young minds to learn about cancer research and discover science as a career path…
18 Oct 2017
Hot off the press: VHIO´s 2014 Scientific Report now available
VHIO´s 2014 Scientific Report is now available either as a PDF (´light´version), or in its extended version online at: /scientific_reports/en_2014.php. Aside…
12 May 2015
